Synthroid and Trazodone Interaction: What You Need to Know
At a glance
- Entities / levothyroxine (Synthroid, brand; generic levothyroxine sodium; class: thyroid hormone replacement) and trazodone (Desyrel, brand; class: serotonin antagonist/reuptake inhibitor, SARI)
- Interaction type / pharmacokinetic (absorption and metabolism), not pharmacodynamic
- Established / levothyroxine absorption is reduced by co-ingestion with many substances taken close in time; it should be taken on an empty stomach, per American Thyroid Association guidance
- Established / TSH monitoring roughly 6-8 weeks after starting or stopping any medication that could plausibly affect levothyroxine handling is standard endocrinology practice
- Plausible but unproven / trazodone's CYP3A4 involvement could theoretically alter thyroid hormone metabolism at higher antidepressant doses, but a levothyroxine-trazodone-specific pharmacokinetic study was not located
- Not established / a specific rate of levothyroxine dose adjustment attributable to trazodone specifically
- Not established / any serotonergic interaction between levothyroxine and trazodone, since levothyroxine is not serotonergic
The direct answer
Levothyroxine and trazodone are commonly prescribed together, and there is no FDA boxed warning or contraindication against the combination. The two drugs work through unrelated mechanisms: levothyroxine replaces thyroid hormone, and trazodone modulates serotonin receptors and reuptake. The main practical issue is timing. Levothyroxine absorption drops when it is taken close in time to many other oral substances, a well-established property of the drug independent of what the co-administered agent is. The routine, guideline-based response to starting any new chronic medication in a patient on levothyroxine is to separate dosing and recheck TSH in 6 to 8 weeks, not to treat trazodone as uniquely hazardous.
What is actually established
The FDA labeling for levothyroxine describes it as having a narrow therapeutic index and notes that many drug classes, including antidepressants broadly, can affect its absorption or metabolism, which is why routine monitoring is recommended whenever a patient's medication regimen changes (according to levothyroxine prescribing information). This is a class-level statement about antidepressants generally. It is not specific evidence about trazodone.
The American Thyroid Association's guideline for hypothyroidism treatment recommends taking levothyroxine on an empty stomach, ideally 30 to 60 minutes before food, and separating it from other oral medications and supplements that are known to interfere with absorption (calcium, iron, proton pump inhibitors, and similar agents have documented absorption effects). Whether trazodone itself materially interferes with levothyroxine absorption was not confirmed against a specific trial in the sources reviewed for this page; the guideline principle of separation is general practice, applied cautiously here rather than as trazodone-specific evidence.
Levothyroxine's elimination half-life is commonly cited as approximately one week, which is why a new steady state after any dosing change, in the drug itself or in a co-medication that might affect its handling, takes roughly 5 to 6 weeks to become fully apparent on a TSH test. This is the basis for checking TSH 6 to 8 weeks after starting trazodone, not because trazodone is known to cause a problem, but because that is the standard interval for any medication change in a patient stabilized on levothyroxine.
Trazodone's FDA label describes standard dosing ranges for insomnia and for depression and describes trazodone's own pharmacology as a serotonin antagonist and reuptake inhibitor with sedative effects tied to bedtime dosing (FDA trazodone/Desyrel label). Nothing in that labeling flags a specific thyroid hormone interaction.
What is pharmacologically plausible but unproven
Trazodone is metabolized in part through CYP3A4. Thyroid hormone metabolism also involves multiple enzymatic pathways, including deiodination and glucuronidation, with CYP-mediated oxidation playing a secondary role. It is pharmacologically plausible that meaningful CYP3A4 induction at higher trazodone doses could modestly increase T4 clearance in theory. However, a study directly measuring this effect for the levothyroxine-trazodone combination was not located for this page, and claims describing a specific percentage of patients requiring dose changes, or a specific magnitude of TSH shift attributable to this pairing, should be treated as unverified until a clinician or pharmacist can point to a primary source. Readers should not take a precise number from this page as clinical fact for this specific combination.
It is similarly plausible that trazodone's effect on serotonin receptors involved in hypothalamic TRH regulation could nudge pituitary TSH secretion in a small way, since serotonergic pathways are known to interact with hypothalamic-pituitary signaling broadly. Whether this produces a measurable, clinically relevant change in patients taking levothyroxine specifically is not established from the sources available here.
What is not established
There is no documented serotonergic interaction between levothyroxine and trazodone. Levothyroxine does not act on serotonin receptors or reuptake transporters, so it does not contribute to serotonin syndrome risk, which requires two or more agents that each increase serotonergic tone. A claim that adverse event databases contain "zero reports" of serotonin syndrome from this specific pairing could not be verified from a located, checkable source and is not repeated here as a factual assertion; the underlying pharmacological reasoning (no shared serotonergic mechanism) is sound on its own and does not require a database count to support it.
A specific rate of levothyroxine dose adjustment needed after starting trazodone, and specific studies purporting to quantify TSH drift from this exact combination, could not be confirmed against a real, checkable paper. Numbers describing "less than 5% of patients" or a specific meta-analysis outcome for this pairing should be verified directly with a pharmacist or the prescribing clinician rather than relied on from this page.
Evidence-status interaction assessment
| Claim | Status | Basis | What to verify before acting |
|---|---|---|---|
| Levothyroxine absorption is reduced by many substances taken close in time | Established | ATA guideline principle; FDA labeling on narrow therapeutic index | Confirm current dosing schedule with prescriber if timing is inconsistent |
| Separating levothyroxine and other oral medications by several hours preserves absorption | Established, general principle | ATA guideline | Ask whether 4 hours is sufficient for your specific other medications, since some interacting substances (iron, calcium, PPIs) may need longer separation |
| TSH recheck 6-8 weeks after any medication change in a levothyroxine patient | Established, standard practice | Reflects levothyroxine's roughly week-long half-life reaching steady state after ~5-6 weeks | Confirm your clinician's specific monitoring plan |
| Trazodone's CYP3A4 involvement could increase T4 clearance at higher doses | Plausible, mechanistically reasonable | General pharmacology of CYP3A4 and thyroid hormone metabolism | Ask your pharmacist whether a trazodone-specific study exists; none was located for this page |
| Trazodone modestly raises nocturnal TSH via serotonergic hypothalamic effects | Plausible, not confirmed for levothyroxine-treated patients specifically | General serotonin-hypothalamic physiology | Do not assume this predicts your individual TSH change; only a follow-up lab value can tell you that |
| A specific percentage of patients needs a levothyroxine dose change after starting trazodone | Not established from sources reviewed | No verifiable primary study located | Ask your prescriber for their clinical experience or a citable reference before treating any percentage as fact |
| Levothyroxine and trazodone together increase serotonin syndrome risk | Not established / mechanistically unsupported | Levothyroxine has no serotonergic activity | If you have concerns, discuss with your prescriber rather than relying on adverse-event counts that were not independently verified for this page |
Practical timing and monitoring approach
To optimize levothyroxine absorption, take it first thing in the morning on an empty stomach with water, then wait 30 to 60 minutes before eating, following ATA guidance. When trazodone is taken at bedtime for insomnia, the overnight interval between the evening dose and the next morning's levothyroxine is typically many hours, which provides adequate separation. For daytime trazodone dosing used to treat depression, maintain at least a few hours between trazodone and levothyroxine, and discuss the optimal timing with your clinician or pharmacist because separation needs may vary depending on the specific formulation and concurrent medications.
A TSH check roughly 6 to 8 weeks after starting or meaningfully changing the trazodone dose is a reasonable, standard step to raise with the prescriber, not because trazodone is known to be hazardous, but because this is the routine approach whenever a levothyroxine patient's medication regimen changes. If TSH stays within the patient's individualized target range, no levothyroxine change is expected to be needed. If TSH drifts outside range on a confirmed repeat test, the prescriber may consider a levothyroxine dose adjustment, typically in small increments, following individualized clinical judgment rather than a fixed formula.
Symptoms that warrant a call rather than watchful waiting
Fatigue, unexplained weight gain, new cold intolerance, or constipation that develops or worsens after starting trazodone could reflect undertreated hypothyroidism and is worth a TSH check rather than being assumed to be a trazodone side effect. Conversely, daytime sedation, dry mouth, or dizziness on standing are more typical trazodone effects and can usually be discussed with the prescriber without an urgent thyroid workup. Any signs of a serious reaction, chest pain, severe allergic symptoms, fainting, or significant confusion, warrant urgent evaluation regardless of which medication is suspected.
What this page cannot tell you
This page cannot tell an individual patient whether their levothyroxine dose needs to change, what interval is safe for their specific formulation, or whether their personal risk factors (age, residual thyroid function, other medications, GI conditions affecting absorption) shift the calculus. Those questions require review by the prescribing clinician or a pharmacist who can see the full medication list and recent labs.
References
- U.S. Food and Drug Administration. Desyrel (trazodone hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018207s032lbl.pdf